These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 31292525)
1. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Takashima Y; Kawaguchi A; Sato R; Yoshida K; Hayano A; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Nakano M; Ogawa S; Tashiro K; Yamanaka R Sci Rep; 2019 Jul; 9(1):10004. PubMed ID: 31292525 [TBL] [Abstract][Full Text] [Related]
2. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer. Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797 [TBL] [Abstract][Full Text] [Related]
4. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848 [No Abstract] [Full Text] [Related]
5. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R PLoS One; 2020; 15(2):e0229577. PubMed ID: 32101576 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. Qiu Y; Li Z; Pouzoulet F; Vishnu P; Copland JA; Knutson KL; Soussain C; Tun HW Br J Haematol; 2018 Nov; 183(4):674-678. PubMed ID: 29076134 [No Abstract] [Full Text] [Related]
7. Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. Takashima Y; Kawaguchi A; Kanayama T; Hayano A; Yamanaka R Oncotarget; 2018 Apr; 9(27):19065-19078. PubMed ID: 29721184 [TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015 [TBL] [Abstract][Full Text] [Related]
10. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832 [TBL] [Abstract][Full Text] [Related]
11. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631 [TBL] [Abstract][Full Text] [Related]
12. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345 [TBL] [Abstract][Full Text] [Related]
13. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434 [TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022 [TBL] [Abstract][Full Text] [Related]
15. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Shimada K; Yoshida K; Suzuki Y; Iriyama C; Inoue Y; Sanada M; Kataoka K; Yuge M; Takagi Y; Kusumoto S; Masaki Y; Ito T; Inagaki Y; Okamoto A; Kuwatsuka Y; Nakatochi M; Shimada S; Miyoshi H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Shiozawa Y; Nannya Y; Okabe A; Kohno K; Atsuta Y; Ohshima K; Nakamura S; Ogawa S; Tomita A; Kiyoi H Blood; 2021 Mar; 137(11):1491-1502. PubMed ID: 33512416 [TBL] [Abstract][Full Text] [Related]
16. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer. Larsen TV; Hussmann D; Nielsen AL Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869 [TBL] [Abstract][Full Text] [Related]
18. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Shi M; Roemer MG; Chapuy B; Liao X; Sun H; Pinkus GS; Shipp MA; Freeman GJ; Rodig SJ Am J Surg Pathol; 2014 Dec; 38(12):1715-23. PubMed ID: 25025450 [TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883 [TBL] [Abstract][Full Text] [Related]
20. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]